Company Of The Day: Pfizer

+19.98%
Upside
49.95
Market
59.93
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer (NYSE:PFE) posted better than expected Q4 2021 earnings, with adjusted EPS coming in at $1.08, up from about $0.43 in Q4 2020. However, revenue growth, which came in at 104% year-over-year, missed estimates.

Why?

Relevant Articles
  1. Should You Buy Pfizer Stock After An Upbeat Q2?
  2. Should You Buy Pfizer Stock Ahead of Its Q2 Results?
  3. Should You Buy, Sell, Or Hold Pfizer Stock At $52?
  4. Here’s A Better Pick Over FedEx Stock
  5. Company Of The Day: Pfizer
  6. What To Expect From Pfizer’s Q1?

Growth was driven primarily by Pfizer’s Covid-19 vaccine. Excluding the vaccine and the new Covid-19 treatment, Pfizer’s revenues actually declined by 2%.

So What?

Pfizer stock declined by about 3% in Tuesday’s trading.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

 Returns Feb 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 PFE Return -2% -12% 59%
 S&P 500 Return 0% -5% 102%
 Trefis MS Portfolio Return 0% -9% 258%

[1] Month-to-date and year-to-date as of 2/9/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates